Disorders of the brain manifest in a variety of manners ranging from feeling or thought abnormalities to total paralysis. Until recently, most imaging methods of the brain have been limited to anatomic considerations, with little information about actual function of the brain except that deduced from clinical examination and physical and cognitive assessment testing. With the advent of positron emission tomography (PET) and enhanced computer and scintigraphic image detection systems, there is keen interest in applying this imaging technique to better understand brain physiology and pathophysiology. Potential applications of PET in CNS assessment is expanding avenues for improved diagnosis and staging of disease, as well as monitoring therapeutic interventions. A general review of the radiopharmaceuticals used for neuro-PET imaging, as well as their application in situations such as cerebrovascular disease, brain activation studies, various movement disorders and dementias, depression, epilepsy, obsessive-compulsive disorder, schizophrenia, and neuropharmacology (including cerebral receptor studies) will be presented.
Orrison WW, Davis LE, Sullivan GW, et al. Anatomic localization of cerebral cortical function by magnetoencephalography combined with MR imaging and CT. AJNR.1990; 11:713-716.
2.
Phelps ME, Hoffman EJ, Mullan NA, et al. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975; 16:210-223.
3.
Raichle ME. Neuroimaging. Trends in Neuroscience. 1986; 525-529.
4.
Frost JJ and Wagner HN Jr., eds. Quantitative Imaging. New York: Raven Press, 1990.
5.
Raichle ME. Quantitative in vivo autoradiography with positron emission tomoraphy. Brain Res. 1979; 1:47-68.
6.
Reivich M, Alavi A, Greenberg J, et al. Use of 18F-fluorodeoxyglucose and 11C-deoxyglucose for the determination of local cerebral glucose consumption in humans. In: Greitz T, Ingvar DH, Widen L, eds. The Metabolism of the Human Brain Studied with Positron Emission Tomography. New York: Raven Press, 1985.
7.
Lear JL, Ackerman RF: Comparison of cerebral glucose metabolic rates measured with fluorodeoxyglucose and glucose labeled in the 1,2,3,4, and 6 positions using quantitative double labeled autoradiography. J Cereb Blood Flow Metab. 1988; 8:575-585.
8.
Ackerman RF and Lear JL. Glycolysis-induced discordance between cerebral glucose metabolic rates measured with fluorodeoxyglucose and glucose. J Cereb Blood Flow Metab. 1989; 9:774-785.
9.
Lear JL and Ackerman RF. Comparison of regional blood-brain transport kinetics between glucose and fluorodeoxyglucose. J Nucl Med. 1992; 33:1819-1824.
10.
Barrio JR. Biochemical principles in radiopharmaceutical design and utilization. In: Phelps M, Mazziotta J, Schelbert H, eds. Positron Emission Tomography: Principles and Applications for the Brain and Heart. New York: Raven Press, 1986.
11.
Martin WRW, Palmer MR, Patlak CS, et al. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol. 1989; 26:535-542.
12.
Raichle ME. The pathophysiology of brain ischemia. Ann Neurol. 1983; 13:2-10.
13.
Wise RJS, Bernardi S, Frackowiak RSJ, et al. Serial observations on the pathophysiology of acute stroke. The transition from ischemia to infarction as reflected in regional oxygen extraction. Brain. 1983; 106:197-222.
14.
Hakim A, Pokrupa R, Villanueva J, et al. The effect of spontaneous reperfusion on metabolic function in early human cerebral infarcts. Ann Neurol. 1987; 21:279-289.
15.
Baron J, Rougemont D, Bousser M, et al. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients. J Cereb Blood Flow Metab. 1984; 4:140-149.
16.
Baron J, Bousser M, Rey A, et al. Reversal of focal “misery-perfusion syndrome” by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. Stroke. 1981; 12:454-459.
17.
Marchal G, Evans A, Dagher A, et al. The evolution of cerebral infarction with time: a PET study of the ischemia penumbra. J Cereb Blood Flow Metab. 1987; 7(Suppl 1):S99.
18.
Kuhl D, Phelps M, Kowell A, et al. Effects of stroke on local cerebral metabolism and perfusion: mapping by emission tomography of 18FDG and 13NH3. Ann Neurol. 1980;8:47-69.
19.
Gibbs JM, Wise RJS, Leenders KL, et al. Evaluation of cerebral perfusion reserve in patients with carotid-artery occlusion. Lancet. 1984;310-314.
20.
Mintun MA, Fox PT, Raichle ME. A highly accurate method of localizing regions of neuronal activation in the human brain with positron emission tomography. J Cereb Blood Flow Metab. 1989; 9:96-103.
21.
Leenders KL, Wolfson L, Gibbs JM, et al: The effects of l-dopa on regional cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease. Brain. 1985; 108:171-191.
22.
Garnett ES, Firnau G, Nahmias C.Dopamine visualizes in the basal ganglia in living man. Nature. 1983; 305:137-138.
23.
Doudet DJ, McLellan CA, Aigner TG, et al. Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-nonspecific fluorine-18-DOPA uptake in man. J Nucl Med. 1992;33:1383-1389.
24.
Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization determined in Parkinson’s disease by the [18F]Fluorodeoxyglucose method. Ann Neurol. 1984; 15:419-424.
25.
Nahmias C, Gernett ES, Firnau G, et al. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci. 1985; 69:223-230.
26.
Leenders KL, Palmer A, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiat. 1986; 49:853-860.
27.
Calne DB, Langstrom JW, Martin WR, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease. Nature. 1985;317:246-248.
28.
Mazziotta JC, Phelps ME, Pahl JJ, et al. Reduced cerebral glucose metabolism in asymptomatic subjectsatrisk for Huntington’s disease. New Engl J Med. 1987;316:357-362.
29.
Hayden MR, Hewitt J, Stoessel A, et al. The combined use of positron emission tomography and DNA polymorphorisms for preclinical detection of Huntington’s disease. Neurology. 1987; 37:1441-1447.
30.
Ter-Pogossian MM. Basic principles of computed axial tomography. Sem Nucl Med. 1986; 7:109-127.
31.
Goffinet AM, De Volder AG, Gillain C, et al. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann Neurol. 1989; 25:131-139.
32.
D’Antona R, Baron JC, Samson Y, et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain. 1985; 108:785-799.
33.
Andreasen NC. Brain imaging: applications in psychiatry. Science. 1988; 239:1381-1388.
34.
Devous MD. Comparison of SPECT applications in neurology and psychiatry. J Clin Psych. 1992; 53(Suppl):13-19.
35.
Lassen NA. Measurement of regional cerebral blood flow in humans with single-photon-emitting radioisotopes. In: Sokoloff L, ed. Brain Imaging and Function. New York: Raven Press, 1985.
36.
Valk PE, Laxer KD, Barbaro NM, et al. High-resolution (2.6 cmm) PET in partial complex epilepsy associated with mesial temporal sclerosis. Radiology. 1993; 186:55-58.
37.
Chugani HT. The use of positron emission tomography in the clinical assessment of epilepsy. Sem Nucl Med. 1992; 22:247-253.
Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Sem Nucl Med. 1992; 22:233-246.
40.
Goldman HH, ed. General Psychiatry. Norwalk, CT: Appleton and Lange, 1988.
41.
Frackiowak R, Pozzilli C, Legg N, et al. Regional cerebral oxygen supply and utilization in dementia: a clinical and physiological study with oxygen-15 and positron tomography. Brain. 1981; 104:753-778.
42.
Benson DF, Kuhl DE, Hawkins RA, et al. The fluorodeoxyglucose 18F scan in Alzheimer’disease and multi-infarct dementia. Arch Neurol. 1983; 40:711-714.
43.
Barker WW, Lowenstein DA, Chang JY, et al. FDG/PET studies of crossed cerebellar hypometabolism in dementia (abstract). Neurology. 1988; 38:364.
44.
Kuhl DE, Metter EJ, Riege WH, et al. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab. 1982; 2:163-171.
45.
Madden DJ, Turkingston IG, Coleman RE, et al. Adult age differences in regional cerebral blood flow among visual word identification: evidence from H2(15)0 PET. Neuroimage. 1996; 3:127-142.
46.
Hopkins A, ed. Clinical Neurology: A Modern Approach. New York: Oxford University Press, 1993.
47.
Morris JH. The Nervous System. In Robbins AL and Kumar V, eds. Basic Pathology. Philadelphia, PA:W.B. Saunders Company, 1987.
48.
Postiglione A, Lassen NA, Holman BL. Cerebral blood flow in patients with dementia of Alzheimer’s type. Aging—Clinical and Experimental Research. 1993; 5(1):19-26.
49.
Holman BL, Devous Sr MD. Functional brain SPECT: the emergences of a powerful clinical method. J Nucl Med. 1992;33:1888-1899.
50.
Holman BL, Johnson KA, Gerada B, et al. The scintigraphic appearance of Alzheimer’s disease: a prospective study using Technetium-99-HMPAO SPECT. J Nucl Med. 1992;33:181-185.
51.
Johnson KA, Holman BL, Rosen TJ, et al. Iofetamine I-123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer’s disease. Arch Intern Med. 1990; 150:752-756.
52.
Dierckx RA, Vandewoude M, Saerens J, et al. Sensitivity and specificity of Tc(m)-99-HMPAO single-headed SPECT in dementia. Nucl Med Comm. 1993; 14:792-797.
53.
Cutler NR, Haxby JV, Duara R, et al. Clinical history, brain metabolism, and neuropsychological function in Alzheimer’s disease. Ann Neurol. 1985; 18:298-309.
54.
Jagust WJ, Friedland RP, Budinger TF, et al. Longitudinal studies of regional cerebral metabolism in Alzheimer’s disease. Neurology. 1988; 38:909-912.
55.
Berent S, Giordani B, Lehtinen S, et al. Positron emission tomographic scan investigations of Huntington’s disease: cerebral metabolic correlates of cognitive function. Ann Neurol. 1988; 23:541-546.
56.
Foster NL, Chase TN, Mansi L, et al. Cortical abnormalities in Alzheimer’s disease. Ann Neurol. 1984; 16:649-654.
57.
Haxby JV, Duara R, Grady CL, et al. Relationship between neuropsychological and cerebral metabolic asymmetries in early Alzheimer’s disease. J Cereb Blood Flow Metab. 1985; 5:193-200.
58.
Duara R, Grady C, Haxby, et al. Positron emission tomography in Alzheimer’s disease. Neurol. 1986; 36:879-887.
59.
Haxby JV, Grady CL, Koss E, et al. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer’s type. Neurology. 1988; 38:1853-1863.
60.
Haxby JV, Grady CL, Duara R, et al. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer’s-type dementia. Arch Neurol. 1986; 43:882-885.
61.
Chawluk JB, Alavi A, Dann R, et al. Positron emission tomography in aging and dementia: effect of cerebral atrophy. J Nucl Med. 1987; 28:431-437.
62.
Fazekas F, Alavi A, Chawluk JB, et al. Comparison of CT, MR and PET in Alzheimer’s dementia and normal aging. J Nucl Med. 1989;30:1607-1615.
63.
Kuhl DE, Metter JM, Benson FD, et al. Similarities of cerebral glucose metabolism in Alzheimer’s and parkinsonian dementia. J Cereb Blood Flow Metab. 1985; 5(Suppl):S169-S170.
64.
De al Monte SM, Wells SE, Hedley-White ET, et al. Neuropathological distinction between Parkinson’s dementia and Parkinson’s plus Alzheimer’s disease. Ann Neurol. 1989; 26:309-320.
65.
Miller BL, Cummings JL, Villanueva-Meyer J, et al. Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics. Neurology1991; 41:1374-1382.
66.
Kamo H, McGeer PL, Harrop, et al. Positron emission tomography and histopathology in Pick’s disease. Neurology. 1987;37:439-445.
67.
Durar R, Gutterman A, Lowenstein D, et al. The clinical and PET scan pattern of probable Pick’s disease. Neurology. 1988; 38(Suppl 1, abstract):415.
68.
Smith FW, Besson JA, Gemmell HG, et al. The use of technetium-99m-HMPAO in the assessment of patients with dementia and other neuropsychiatric conditions. J Cereb Blood Flow Metab. 1988; 8(Suppl 1):S116-S122.
69.
Neary D, Snowden JS, Shields RA, et al. Single photon emission tomography using 99mTc-HMPAO in the investigation of dementia. J Neurol Neurosurg Psychiatry. 1987; 50:1101-1110.
70.
Grunwald F, Horn R, Reiker O, et al. HMPAOSPECT in dementia of the Alzheimer type and major depression with memory impairment [abstract]. Nuklearmedizin. 1993; 32:128-133.
71.
Mozely PD. SPECT brain imaging in patients with depression. In St. Vincent’s Hospital CE Program. A Seminar from the American Psychiatric Association’s43rd Institute on Hospital and Community Psychiatry: October 19, 1991. Los Angeles, California, 1991.
72.
Kuhl DE, Phelps ME, Markham CH, et al. Cerebral metabolism and atrophy in Huntington’s disease determined by 18-FDG and computed tomographic scan, Ann Neurol. 1982; 12:425-434.
73.
Garnett ES, Firnau G, Nahmias C, et al. Reduced striatal glucose consumption and prolonged reaction time are early features in HD. J Neurol. 1984; 65:231-237.
74.
Clark CM, Hayden MR, Stoessel AJ, et al. Regression model for predicting dissociations of regional cerebral glucose metabolism in individuals at risk for Huntington’s disease. J Cereb Blood Flow Metab. 1986; 6:756-762.
75.
Mazziotta JC, Phelps ME, Pahl JJ, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. N Engl J Med. 1987;316:357-362.
76.
Hawkins RA, Mazziotta JC, Phelps ME: Wilson’s disease studied with FDG and positron emission tomography. Neurology. 1987;37:1707-1711.
77.
Benson DF, Mazziotta JC. Positron emission tomographic scanning in the diagnosis of Jakob-Creutzfeldt disease (abstract). Ann Neurol. 1991; 30:238.
78.
Brunetti A, Berg G, Di Chiro G, et al. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3’-azido-2’3’dideoxythymidine (AZT, Zidovudine): a PETFDG study. J Nucl Med. 1989;30:581-590.
79.
Pascal S, ResnickL, Barker WW, et al. Metabolic asymmetries in asymptomatic HIV-1 seropositive subjects: relationship to disease onset and MRI findings. J Nucl Med. 1991;32:1725-1729.
80.
Bench CJ, Friston KJ, Brown RG, et al. The anatomy of melancholia-focal abnormalities of cerebral blood flow in major depression. Psychol Med. 1992; 22:606-615.
81.
Baxter LR, Phelps ME, Mazziotta JC, et al. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F18. Arch Gen Psychiatry. 1985; 42:441-447.
82.
Martinot JL, Hardy P, Felin A, et al. Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am J Psychiatry. 1990; 147:1313-1317.
83.
Devous MD, Gullion CM, Granneman B, et al. Regional cerebral blood flow alterations in unipolar depression. J Nucl Med. 1991;32:951-952.
84.
Foa EB, Wilson R, Barlow DH, eds. Stop Obsessing: How to Overcome Your Obsessions and Compulsions. New York, NY: Bantam Books, 1991.
85.
Baxter LR, Schwartz JM, Guze BH, et al. PET imaging in obsessive disorder with and without depression. J Clin Psychiatry. 1990; 51:61-68.
86.
Baxter LR. Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder. J Clin Psychiatry. 1190; 51(Suppl):S22-S25.
87.
Baxter LR, Schwartz JM, Mazziotta JC, et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry. 1988; 145:1560-1563.
88.
Woods SW. Regional cerebral blood flow imaging with SPECT in psychiatric disease: focus on schizophrenia, anxiety disorders, and substance abuse. J Clin Psychiatry. 1992; 53(Suppl):S20-S25.
89.
Harris GJ, Camargo EE, Machlin SR, et al. SPECT imaging of prefrontal cerebral blood flow in obsessive compulsive disorder. J Nucl Med. 1990; 31:750.
90.
Goodman WK, McDougle CJ, Price LH, et al. SPECT imaging of obsessive-compulsive disorder with Tc-99m d, l-HMPAO. J Nucl Med1990; 31:750-751.
91.
Van Heertum RL. Brain SPECT imaging and psychiatry. J Clin Psychiatry. 1992; 53(Suppl):S7-S12.
92.
Villemagne VL, Dannals RF, Sanchez-Roa PM, et al: Imaging histamine H1 receptors in the living human brain with carbon-11-pyrilamine. J Nucl Med. 1991; 23:308-311.
93.
Bajc M, Medved V, Basic M, et al. Cerebral perfusion inhomogenities in schizophrenia demonstrated with single photon emission computed tomography and Tc99m-hexamethylpropyleneamineoxime. Acta Psychiatry Scandinavia. 1989;80:427-433.
94.
Buchsbaum M.The frontal basal ganglia, and temporal lobes as sites for schizophrenia. The Schizophrenia Bulletin. 1990; 16:379-387.
95.
Gur RE, Resnick SM, Alavi A, et al. Regional brain function in schizophrenia. I. A positron emission tomography study. Arch Gen Psychiatry. 1987; 44:119-125.
96.
Andreasen NC. Linking mind and brain in the study of mental illness: a project for a scientific psychopathology. Science. 1997; 275:1586-1593.
97.
Van Rossum JM. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 1966; 160:492-494.
98.
Carlsson A.Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psych. 1978; 135:164-173.
99.
Wiessel F-A, Blomqvist G, Halldin C, et al. The transport into the human brain as determined with L-[11C]tyrosine and PET. J Nucl Med. 1991; 32:2043-2049.
100.
Wong DF, Wagner HN Jr, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naïve schizophrenics. Science. 1986; 234:1558-1563.
101.
Farde L, Hall H, Ehrin E, et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986; 231:258-261.
102.
Cohen MB, Lake RR, Graham LS, et al. Quantitative iodine-123 IMP imaging of brain perfusion in schizophrenia. J Nucl Med. 1989; 30:1616-1620.
103.
Mulholland GK, Otto CA, Jewett DM, et al. Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2alpha-tropanyl benzilate: a central muscarinic receptorimagingagent. J Nucl Med. 1992; 33:423-430.
104.
Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989; 4:371-377.
105.
Volkow ND, Fowler JS. Neuropsychiatric disorders: investigation of schizophrenia and substance abuse. Sem Nucl Med. 1992; 22:254-267.
106.
Volkow ND, Mullani N, Gould KL, et al. Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry. 1988; 152:641-648.
107.
Volkow ND, Fowler JS, Wolf AP, et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry. 1991; 148:621-626.
108.
Volkow ND, Hitzemann R, Wolf AP, et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse. 1992; 11:184-190.
109.
Volkow ND, Fowler JS, Wolf AP, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry. 1990; 147:719-724.
110.
Baxter LR, Schwartz JM, Phelps ME, et al. Localization of neurochemical effects of cocaine and other stimulants in the human brain. J Clin Psychiatry. 1988; 49:23-26.
111.
Dachis CA and Gould MS: New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev. 1985; 9:469-477.
112.
Volkow ND, Hitzemann R, Wang G-J, et al. Decreased brain metabolism in neurologically intact healthy alcoholics. Am J Psychiatry. 1992; 149:1016-1022.
113.
Sachs H, Russell JAG, Christman DR, et al. Alteration of regional cerebral glucose metabolic rate in non-Korsakoff chronic alcoholism. Arch Neurol. 1987; 44:1242-1251.
114.
Volkow ND, Fowler JS. Use of PET to study addiction in human. In London ED, ed. Imaging Drug Addiction in the Brain. Boca Raton, FL: CRC Press, 1993.
115.
Nyback H, Nordberg A, Lanstrom B, et al. Nicotine binding in the living human brain as studied by positron emission tomography. J Nucl Med. 1989;30:742.
116.
Wu JC, Buchsbaum MS, Bunney WE. PET scan study of patients on phencyclidine. Soc Neurosci Abstr. 1989; 15:448.
117.
Phelps ME, Mazziotta JC, Baxter L, et al. Study design in the investigation of mood disorders with PET. In Sokoloff L, ed, Brain Imaging and Function. New York, NY: Raven Press, 1985.
118.
Caldwell JH, Kroll K, Li-Z, et al. Quantitation of presynaptic cardiac sympathetic function with carbon-11-meta-hydroxyephedrine. J Nucl Med. 1998; 39(8):1327-1334.
119.
Berry CR, Garg PK, Zalutski MR, et al. Uptake and retention kinetics of para-fluorine-18-fluorobenzyguanidine in isolated rat heart. J Nucl Med. 1996;37(12):2011-2016.
120.
Abadie P, Baron JC, Bisserbe JC, et al. Central benzodiazepine receptors in human brain: estimation of regional Bmax and Kd values with positron emission tomography. Eur J Pharmacol. 1992; 213:107-115.
121.
Delforge J, Syrota A, Bottlaender M, et al. Modeling analysis of [11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. J Cerebral Blood Flow Metab. 1993; 13:454-468.
122.
Delforge J, Spelle L, Bendriem B, et al. Quantitation of benzodiazepine receptors in human brain using the partial saturation method. J Nucl Med. 1996;37:5-11.
123.
Comar D, Maziere M, Cepeda C, et al. The kinetics and displacement of [11C]flunitrazepam in the brain of the living baboon. Eur J Pharmacol. 1981; 75:21-26.
124.
Buck A, Westera G, vonSchulthess GK, et al. Modeling alternatives for cerebral carbon-11 iomazenil kinetics. J Nucl Med. 1996;37:699-705.
125.
Farde L, Halldin C, Stone-Elander S, et al. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology. 1987; 92:278-284.
126.
Laihinen AO, Rinne JO, Ruottinen HM, et al. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med. 1994;35:1916-1920.
127.
Volkow ND, Fowler JS, Logan J, et al. Carbon-11-cocaine binding compared at subpharmacological and pharmacological doses: a PET study. J Nucl Med. 1995;36:1289-1297.
128.
Bahn MM, Huang SC, Hawkins RA, et al. Models for in vivo kinetic interactions of dopamine D2-neuroreceptors and 3-(2’-[18F]fluoroethyl)-spiperone examined with positron emission tomography. J Cerebral Blood Flow Metab. 1989; 9:840-849.
129.
Eckernas SA, Aquilonius SM, Hartvig P, et al. Positron emission tomography (PET) in the study of dopamine receptors in the primate brain: evaluation of a kinetic model using 11C-N-methyl-spiperone. Acta Neurol Scand. 1987; 75:168-178.
130.
Wong DF, Gjedde A, Wagner HM, et al. Technical comments: elevated D2 dopamine receptors in drug-naïve schizophrenics (response). Science. 1988; 239:790-791.
131.
Watabe H, Endres CJ, Breier A, et al. Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med. 2000; 41:522-530.
132.
Goyer PF, Berridge MS, Morris ED, et al. PET measurements of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med. 1996; 37:1122-1127.
133.
Watabe H, Hatazawa J, Ishiwata K, et al. A new approach for kinetic analysis of central dopamine D2 receptor specific binding. IEEE Trans Med Imaging. 1995; 14(4):688-696.
134.
Baron JC, Comar D, Zarifian E, et al. Dopaminergic receptor sites in human brain: positron emission tomography. Neurology. 1985; 35:16-24.
135.
Baron JC, Martinot JL, Cambon H, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology. 1989; 99:463-472.
136.
Arnett CD, Wolf AP, Shiue CY, et al. Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET. J Nucl Med. 1986; 27:1878-1882.
137.
Brownell AL, Elmaleh DR, Meltzer PC, et al. Cocaine congeners as PET imaging probes for dopamine terminals. J Nucl Med. 1996; 37:1186-1192.
138.
Volkow ND, Ding YS, Fowler JS, et al. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med. 1995; 36:2162-2168.
139.
Goodman MM, Keil R, Shoup TM, et al. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J Nucl Med. 1997;38:119-126.
140.
Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998; 39:1521-1530.
141.
Villemagne VL, Dannals RF, Sanchez-Roa PM, et al. Imaging histamine H1 receptors in the living human brain with carbon-11-pyrilamine. J Nucl Med. 1991;32:308-311.
142.
Raffel DM, Corbett JR, del Rosario RB, et al. Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med. 1996;37:1923-1931.
143.
Arnett CD, Fowler JS, MacGregor RR, et al. Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl. J Neurochemistry. 1987; 49:522-527.
144.
Laihinen AO, Rinne JO, Nagren KA, et al. PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson’s Disease. J Nucl Med. 1995;36:1263-1267.
145.
Vander Borght TM, Kilbourn MR, Koeppe RA, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med. 1995; 36:2252-2260.
146.
Dewey SL, MacGregor RR, Brodie JD, et al. Mapping muscarinic receptors in human and baboon brain using [N-11Cmethyl]-benztropine. J Nucl Med. 1990;31:983-988.
147.
Zubieta JK, Koeppe RA, Mulholland GK, et al. Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding. J Cerebral Blood Flow Metab. 1998; 18:619-631.
148.
Frey KA, Minoshima S, Koeppe RA, et al. Stereotaxic summation analysis of human cerebral benzodiazepine binding maps. J Cerebral Blood Flow Metab. 1996; 16:409-417.
149.
Carson RE, Kiesewetter DO, Jagoda E, et al. Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies. J Cerebral Blood Flow Metab. 1998; 18:1130-1142.
150.
Horti A, Scheffel U, Stathis M, et al. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. J Nucl Med. 1997;38:1260-1265.
151.
Vogt BA, Watanabe H, Grootoonk S, et al. Topography of diprenorphine binding in human cingulate gyrus and adjacent cortex derived from coregistered PET and MR images. Human Brain Mapping. 1995;3:1-12.
152.
Kim S, Wagner HN, Villemagne VL, et al. Longer occupancy of opiod receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med. 1997; 38:1726-1731.
153.
Farde L, Ito H, Swahn CG, et al. Quantitative analyses of carbonyl-carbon-11-WAY-100635 to central 5-hydroxytryptamine-1A receptors in man. J Nucl Med. 1998; 39:1965-1971.
154.
Baron JC, Samson Y, Crouzel C, et al. Pharmacologic studies in man with PET: an investigation using 11C-labeled ketanserin, a 5HT2 receptor antagonist. J Cerebral Blood Flow Metab. 1985; 5:471-480.
155.
Sadzot B, Lemaire C, Maquet P, et al. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J Cerebral Blood Flow Metab. 1995; 15:787-797.
156.
Petit-Taboue MC, Landeau B, Osmontet al. Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. J Nucl Med. 1996;37:95-104.
157.
Blin J, Sette G, Fiorelli M, et al. A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. J Neurochem. 1990; 54:1744-1754.
158.
Barre L, Debruyne D, Lasne MC, et al. Synthesis and regional rat brain distribution of [11C]MDL 72222: a 5HT3 receptor antagonist. Appl Radiat Isot, Int J Radiat Appl Instrum Part A. 1992; 43(4):509-516.
